{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T12:18:10Z","timestamp":1795177090067,"version":"4.10.3"},"reference-count":9,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2023.284436","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T04:29:01Z","timestamp":1708576141000},"page":"2368-2371","source":"Crossref","is-referenced-by-count":13,"title":["Phenomenon of tumor flare with talquetamab in a patient with extramedullary myeloma"],"prefix":"10.3324","volume":"109","author":[{"given":"Mark","family":"Forsberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mendel","family":"Goldfinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Janakiram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Kalbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"63872","unstructured":"Howlader N, Noone AM, Krapcho M. SEER cancer statistics review (CSR) 1975-2018. Cronin KA eds. 2020."},{"key":"63873","doi-asserted-by":"crossref","unstructured":"Kegyes D, Constantinescu C, Vrancken L. Patient selection for CAR T or BiTE therapy in multiple myeloma: which treatment for each patient?. J Hematol Oncol. 2022; 15(1):78.","DOI":"10.1186\/s13045-022-01296-2"},{"key":"63874","doi-asserted-by":"crossref","unstructured":"Chari A, Minnema MC, Berdeja JG. Talquetamab, a T-cell\u2013 redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022; 387(24):2232-2244.","DOI":"10.1056\/NEJMoa2204591"},{"key":"63875","doi-asserted-by":"crossref","unstructured":"Chanan-Khan A, Miller KC, Takeshita K. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia CLL. Blood. 2005; 106(10):3348-3352.","DOI":"10.1182\/blood-2005-02-0669"},{"key":"63876","doi-asserted-by":"crossref","unstructured":"Wolchok JD, Hoos A, O\u2019Day S. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15(23):7412-7420.","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"63877","doi-asserted-by":"crossref","unstructured":"Budde LE, Assouline S, Sehn LH. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study. J Clin Oncol. 2022; 10(5):481-491.","DOI":"10.1200\/JCO.21.00931"},{"key":"63878","doi-asserted-by":"crossref","unstructured":"Aue G, Njuguna N, Tian X. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica. 2009; 94(9):1266-1273.","DOI":"10.3324\/haematol.2009.005835"},{"key":"63879","doi-asserted-by":"crossref","unstructured":"Leipold AM, Werner RA, D\u00fcll J. Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma. Leukemia. 2023; 37(3):650-658.","DOI":"10.1038\/s41375-023-01824-0"},{"key":"63880","doi-asserted-by":"crossref","unstructured":"Jamet B, Bodet-Milin C, Moreau P, Kraeber-Bod\u00e9r\u00e9 F, Touzeau C. 2-[18F]FDG PET\/CT flare-up phenomena following T-cell engager bispecific antibody in multiple myeloma. Clin Nucl Med. 2023; 48(5):e230-e231.","DOI":"10.1097\/RLU.0000000000004588"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284436\/76634","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284436\/77235","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11466\/76634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:47Z","timestamp":1794045947000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":9,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284436","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,22]]}}}